MedTrace Logo

Clinical Study of Stellate Ganglion Block in Treatment of Patients With Advanced Primary Parkinson's Disease

NCT06112392 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2024-01-31

No results posted yet for this study

Summary

At present, there are no reports on the application of stellate ganglion block in the treatment of Parkinson's disease patients at home and abroad. Based on the preliminary clinical observation, this project intends to apply stellate ganglion block in the treatment of patients with intermediate and advanced Parkinson's disease through an open, randomized controlled small sample clinical study. To determine whether stellate ganglion block can effectively improve motor symptoms and non-motor symptoms in patients with primary advanced Parkinson's disease.

Conditions

  • Stellate Ganglion
  • Parkinson Disease

Interventions

DIAGNOSTIC_TEST

Treatment （Stellate ganglion block；Oral standard anti-Parkinson's drugs）

Treatment （Stellate ganglion block；Oral standard anti-Parkinson's drugs）

DIAGNOSTIC_TEST

Treatment （Oral standard anti-Parkinson's drugs）

Treatment （Oral standard anti-Parkinson's drugs）

Sponsors & Collaborators

  • Zhujiang Hospital

    lead OTHER

Principal Investigators

  • Xiaoya Gao, doctor · Southern Medical University, China

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-07-28
Primary Completion
2024-06-30
Completion
2024-06-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06112392 on ClinicalTrials.gov